PET Imaging in the Management of Neuroendocrine Tumors, An Issue of PET Clinics, 1st Edition
Authors :
Stefano Fanti & Cristina Nanni & Richard P. Baum
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and
...view more
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.
Author Information
By Stefano Fanti, Intitute of Nuclear Medicine, University of Bologna, Italy; Cristina Nanni, MD, Nuclear Medicine Department, Intitute of Nuclear Medicine, University of Bologna, Italy and Richard P. Baum, MD, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Germany
https://www.us.elsevierhealth.com/pet-imaging-in-the-management-of-neuroendocrine-tumors-an-issue-of-pet-clinics-9780323264044.html1070PET Imaging in the Management of Neuroendocrine Tumors, An Issue of PET Clinicshttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9780323264044.jpg79.1998.99USDInStock/Medicine/Radiology/Clinics/Clinics4243887255255041Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics. Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.00add-to-cart97803232640442013ProfessionalBy Stefano Fanti, Cristina Nanni, MD and Richard P. Baum, MD20141Book178w x 254hElsevier0Dec 1, 2013IN STOCK - This may take up to 5 business days to shipBy <STRONG>Stefano Fanti</STRONG>, Intitute of Nuclear Medicine, University of Bologna, Italy; <STRONG>Cristina Nanni</STRONG>, MD, Nuclear Medicine Department, Intitute of Nuclear Medicine, University of Bologna, Italy and <STRONG>Richard P. Baum</STRONG>, MD, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, GermanyClinicsClinicsThe Clinics: RadiologyNoNoNoNoPlease SelectPlease SelectPlease Select
